The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.La présente invention concerne une association de composés thérapeutiques et des procédés de traitement et des kits utilisant lassociation. En particulier, lune des associations affecte le canal NCca-ATP du tissu nerveux, dont les neurones, la névroglie et les vaisseaux sanguins présents à lintérieur du système nerveux. Des antagonistes de SUR1 et/ou TRPM4 qui inhibent le canal NCca-ATP peuvent être par exemple employés dans lassociation. La thérapie combinée emploie également un ou plusieurs bloqueurs de canal cationique non sélectif et/ou antagonistes du VEFG, de la NOS, des MMP ou de la thrombine. Les indications pour la thérapie combinée comprennent par exemple la prévention, la diminution et/ou le traitement dune blessure ou maladie du tissu nerveux, dont les astrocytes, les neurones e
